answer text |
<p>Information is not held centrally on the number of people treated with warfarin
or novel oral anticoagulants. The following table provides information on the number
of prescription items written in England and dispensed in the community in the United
Kingdom, for the latest calendar year, for apixaban, dabigatran etexilate, rivaroxaban,
and warfarin sodium.</p><p> </p><table><tbody><tr><td colspan="2"><p>Prescription
items written in England and dispensed in the community in the United Kingdom for
2013 <sup>1</sup></p></td></tr><tr><td><p>Medicine <sup>2</sup></p></td><td><p>Items
(000s)</p></td></tr><tr><td><p>Apixaban</p></td><td><p>14.4</p></td></tr><tr><td><p>Dabigatran
etexilate</p></td><td><p>174.0</p></td></tr><tr><td><p>Rivaroxaban</p></td><td><p>190.0</p></td></tr><tr><td><p>Warfarin
sodium <sup>3</sup></p></td><td><p>11,022.8</p></td></tr><tr><td><p>Total for apixaban,
dabigatran etexilate, rivaroxaban, and warfarin sodium</p></td><td><p>11,401.2</p></td></tr><tr><td><p>Percentage
of warfarin sodium compared to the total for apixaban, dabigatran etexilate, rivaroxaban,
and warfarin sodium</p></td><td><p>96.7%</p></td></tr></tbody></table><p><em> </em></p><p><em>Source:</em>
ePACT and Hospital ePACT, NHS Prescription Services, part of the NHS Business Services
Authority</p><p><em> </em></p><p><em>Notes:</em></p><p><sup>1. </sup>The figures include
prescriptions written in a hospital in England but dispensed in the community in the
United Kingdom.</p><p><sup>2. </sup>These medicines are also used in secondary care,
however no equivalent measure to a prescription item is available for secondary care
data.</p><p>Some patients treated with warfarin may receive prescription items for
two or three different strengths of warfarin to allow the dose to be altered in response
to monitoring of INR. (NB: warfarin is available as 0.5mg, 1mg, 3mg and 5mg tablets).</p>
|
|